Within a year he’d launch his own startup in Shanghai, with a foundational licensing deal and financing from Celgene. Two more rounds totaling $141 million later, with Celgene now part of Bristol Myers Squibb and Alles now sitting on the board, Antengene is shooting for an IPO in Hong Kong (rather than Nasdaq, an option that Mei said was equally likely back in 2018).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,